🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are escalating around the world, with figures suggesting in excess of 82 million instances per year. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is additionally indicated for UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a major breakthrough in the therapy of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

As per findings detailed in a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This places it at an equal footing with the current standard treatment, which uses a dual-drug approach. The research enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors on the front lines have expressed hope. Access to a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is deemed vital to alleviate the strain of the infection for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.